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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMTARGET I RCT (n¼227), TARGET I long stent cohort (n¼50), and TARGET II
registry (n¼730) was prospectively collected and analyzed in 1007 patients with de
novo native coronary lesions. All patients were exclusively treated with FIRE-
HAWK stent and the follow-up visits are at 1-, 6-, 12-month, and annually up to
5 years.
Results: 992 (98.5%) patients completed 2-year clinical follow-up. Between 1 and
2 years, 62% of patients discontinued DAPT and there were only 7 newly
occurred TLF events including 3 cardiac death, 1 TV-MI and 3 iTLR (table).
Importantly, no deﬁnite/probable stent thrombosis (ST) was observed in this cohort
5 days after implantation of FIREHAWK stents. Lesion length >¼30mm was
an independent predictor of TLF at 2 years (HR [95%CI]: 2.44 [1.32, 4.53],
p< 0.01).Table. Clinical Outcomes through 2 Years
1 Year 2 Years
(n¼1003) (n¼992)
Death, % (n) 0.8 (8) 1.4 (14)
Cardiac Death, % (n) 0.5 (5) 0.8 (8)
Myocardial Infarction, % (n) 2.8 (28) 3.1 (31)
Q Wave MI, % (n) 0.1 (1) 0.4 (4)
Non Q Wave MI, % (n) 2.7 (27) 2.7 (27)
Target Vessel MI, % (n) 2.8 (28) 2.9 (29)
Ischemia-Driven TLR, % (n) 0.9 (9) 1.2 (12)
Any Revascularization, % (n) 2.9 (29) 4.1 (41)
TLF, % (n) 3.9 (39) 4.6 (46)
PoCE (All-Cause Death / All Myocardial Infarction / Any
Revascularization), % (n)
4.1 (41) 7.8 (77)
Deﬁnite/Probable ST, % (n) 0.1 (1) 0.1 (1)Conclusions: The sustained 2-year clinical data indicates that FIREHAWK stent
could enable safety and efﬁcacy by a novel target eluting technology in mild to
moderate risk patients. However, large scale randomized trials (TARGET EU and III)
are needed to further conﬁrm its clinical beneﬁts in treating most complex patients/
lesions.TCT-606
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Background: In this randomized controlled study (RCT) we compare the clinical
efﬁcacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime
Everolimus Eluting Stent (Xience) at 2 years in the complete study population as well
as in the diabetic and small vessel subgroups, which are known to have a higher risk
for cardiac complications.
Methods: A total of N¼458 subjects (63.410.0SD 36-80 yrs) were enrolled in
the BIOFLOW-II study, registered at clinicaltrials.gov (NCT01356888). All sub-
jects were stratiﬁed for diabetes and then randomly assigned (2:1) to receive the
Orsiro or the Xience stent. Six patients were excluded from the intention to treat
population. The diabetic subgroup accounted for 28.3% N¼128 (Orsiro N¼84,
Xience N¼44) of all subjects. The small vessel cohort included all subjects with a
reference vessel diameter 2.75mm, accounting for 57.3% N¼259 (Orsiro N¼168,
Xience N¼91) of all subjects. Clinical follow up visits are performed at 1, 6, 12
months and annually for up to 5 years after the procedure. All angiographic im-
ages were analyzed by the core lab of R. Waksman, MD at MedStar HealthJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteResearch Institute, Washington DC, USA. All clinical events were adjudicated by
3 independent cardiologists (MD:s).
Results: All three study groups showed comparable populations in both randomi-
zation arms in terms of demographics, current risk factors, clinical history and lesion/
vessel characteristics. The clinical endpoint of Target Lesion Failure (TLF) for
Orsiro vs Xience at 12 month in the three analyzed populations were: All patients –
6.5% for the Orsiro vs 8.0% for the Xience (p 0.5832) Diabetic subgroup - 6.0%
for the Orsiro vs 4.5% for the Xience (p 0.7201) Small vessel subgroup – 7.4% for
the Orsiro vs 12.3% for the Xience (p 0.2065) No stent thrombosis (deﬁnitive,
probable or possible) occurred through 12 months. The clinical 2-year follow up data
is currently being analyzed. Results will be presented for the ﬁrst time during the
meeting.
Conclusions: In this RCT the clinical event rates of the Orsiro SES with a biode-
gradable polymer the clinical event rates were low and comparable to the Xience
Prime through 12 months in all three analyzed populations.
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Background: Bioresorbable polymer coatings are hoped to minimize persistent
inﬂammation associated with durable polymer usage as a drug carrier in drug-
eluting stents (DES). We examined the time course of para-strut inﬂammation (PI)
of 3 contemporary DES featuring abluminal bioresorbable polymer coating
(SYNERGYTM ¼SY) and durable polymer coating (XIENCE PRIME¼EES and
RESOLUTE INTEGRITY¼ZES) in the familial hypercholesterolemic swine (FHS)
model.
Methods: Stents (SE¼29, EES ¼29, ZES¼29 and OMEGA BMS¼29) were
implanted in 87 coronary arteries in 29 FHS. Para-strut inﬂammation (PI) was deﬁned
as contiguous regions of inﬂammation in contact with, or surrounding struts, and
extending into the neointima, media or adventitia and examined histologically at 30,
90 and 180 days.
Results: At 30 days, PI was higher in BMS compared to the 3 DES. By 90 days, PI
had markedly subsided in the BMS, but peaked in all 3 DES groups. At 180 days, PI
in the SY resolved to a minimal level comparable to BMS (p¼0.95), while the other 2
DES continued to show higher average PI scores than SY and BMS (EES vs. SY p<
0.0001 and ZES vs. SY p¼0.03).
Conclusions: In the setting of early atherosclerosis present in the FHS model at the
age used (12-25 months at implant), the peak PI in DES is delayed in comparison to
BMS and its resolution is slower. Polymer resorption and lower total mass of the
abluminally applied polymer coating in SY appear to accelerate the resolution of PI as
projected, adding to the evidence that FHS is capable of modeling clinically relevant
responses to endovascular interventions.TCT-608
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